BASF Completes Acquisition of DOMO Chemicals' Shares in Alsachimie JV

BASF has acquired DOMO Chemicals' 49% stake in the Alsachimie joint venture and is now the sole owner of the production company for essential precursors of polyamide (PA) 6.6, including KA oil, adipic acid and hexamethylenediamine adipate (AH salt) in Chalampé, France. The parties have agreed not to disclose financial details of the transaction.

With the full acquisition of Alsachimie, BASF strengthens its operational presence at the Chalampé site - the European center for PA 6.6 production. The strategic decision enables BASF to optimize the backward integration of key raw materials and thus ensure a reliable and efficient supply along the PA 6.6 value chain. For DOMO Chemicals, the transaction is in line with its strategy to continue to focus on customized polyamide solutions for core segments such as the automotive, consumer goods, industrial goods and electrical and electronics industries.

The transaction complements a number of strategic measures taken by BASF to further strengthen PA 6.6 production at the Chalampé site, including the newly opened state-of-the-art hexamethylenediamine (HMD) plant and the expansion of PA 6.6 polymerization capacity at the nearby site in Freiburg, Germany.

Location in Chalampé, France
Location in Chalampé, France
© BASF

Company

BASF SE

Avenue de Cortenbergh 60
1000 Bruxelles
Belgium

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.